Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
2.980
-0.060 (-1.97%)
Aug 24, 2026, 4:00 PM EDT - Market closed
Elicio Therapeutics Stock Forecast
ELTX's stock price has decreased by -74.75% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 4 analysts polled by S&P Global, Elicio Therapeutics stock has a consensus rating of "Buy" and an average price target of $16.5. The average 1-year stock price forecast is 453.69% higher than the current stock price, while the lowest is $10 (+235.57%) and the highest is $23 (+671.81%).
Price Target: $16.5 (+453.69%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Elicio Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $23 | Buy | Reiterates | $23 | +671.81% | Aug 21, 2026 |
| JonesTrading | JonesTrading | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 17, 2026 |
| Ladenburg Thalmann & Co. | Ladenburg Thalmann & Co. | Buy Initiates $12 | Buy | Initiates | $12 | +302.68% | Jun 18, 2026 |
| B. Riley Securities | B. Riley Securities | Buy Initiates $27 | Buy | Initiates | $27 | +806.04% | Jun 10, 2026 |
| Rodman & Renshaw | Rodman & Renshaw | Buy Initiates $17 | Buy | Initiates | $17 | +470.47% | Mar 9, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.95
from -2.58
EPS Next Year
-2.17
from -1.95
EPS and Forward PE are based on non-GAAP adjusted numbers.